Safety Information

Safety Information

 


Medical Product
Reporting

Reporting Adverse Events to the FDA

Welcome to MedWatch, your Internet gateway for timely safety information on the drugs and other medical products regulated by the U.S. Food and Drug Administration.

A Message About HIPAA Compliance for Reporters to FDA MedWatch New

FDA Logo links to FDA home page
U.S. Food and Drug Administration
  HHS Logo links to Department of Health and Human Services website
 MedWatch logoThe FDA Safety Information and Adverse Event Reporting Program


Join the E-list
Get safety alerts by e-mail

What's New

Mifeprex (mifepristone) - Revisions to the BOXED WARNING, WARNINGS, MEDICATION GUIDE, and PATIENT AGREEMENT sections of the prescribing information, describing serious and sometimes fatal infections and bleeding that may occur following the use of Mifeprex.
(Posted 11/15/2004)

Humira (adalimumab) - Revisions to the WARNINGS section of the prescribing information to include reports of serious infections, hypersensitivity reactions, pancytopenia and aplastic anemia.
(Posted 11/08/2004)

Actra-Rx and Yilishen dietary supplements - FDA warned consumers not to purchase or to consume Actra-Rx or Yilishen, dietary supplements which contain the prescription drug ingredient sildenafil. The interaction between sildenafil and certain prescription drugs may cause a significant lowering of blood pressure to an unsafe level.
(Posted 11/4/2004)

 
horizonal rule